Mainz Biomed Files H1 2025 Financial Report
Ticker: MYNZ · Form: 6-K · Filed: Sep 26, 2025 · CIK: 1874252
| Field | Detail |
|---|---|
| Company | Mainz Biomed N.V. (MYNZ) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, 6-K, disclosure
TL;DR
Mainz Biomed dropped its H1 2025 financials on 9/26 - check it out.
AI Summary
On September 26, 2025, Mainz Biomed N.V. filed a Form 6-K to provide its Management's Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025. This report details the company's financial performance and operational status during the first half of 2025.
Why It Matters
This filing provides investors with an update on Mainz Biomed's financial health and operational progress for the first half of 2025, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Mainz Biomed N.V. (company) — Filer of the report
- June 30, 2025 (date) — End of the reporting period
- September 26, 2025 (date) — Date of the filing and report availability
FAQ
What specific financial details are provided in the Management's Discussion and Analysis?
The filing states that the Management's Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025, was made available, but the specific details are within the attached Exhibit 99.1.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country or to shareholders.
What period does this report cover?
This report covers the six months ended June 30, 2025.
When was this report filed with the SEC?
The report was filed on September 26, 2025.
Does Mainz Biomed N.V. file annual reports under Form 20-F or 40-F?
Yes, Mainz Biomed N.V. files annual reports under cover of Form 20-F, as indicated by the checked box in the filing.
Filing Stats: 354 words · 1 min read · ~1 pages · Grade level 7.9 · Accepted 2025-09-26 17:00:20
Filing Documents
- ea0258521-6k_mainz.htm (6-K) — 23KB
- ea025852101ex99-1_mainz.htm (EX-99.1) — 78KB
- ea025852101ex99-2_mainz.htm (EX-99.2) — 826KB
- 0001213900-25-092425.txt ( ) — 6377KB
- mynz-20250630.xsd (EX-101.SCH) — 108KB
- mynz-20250630_cal.xml (EX-101.CAL) — 43KB
- mynz-20250630_def.xml (EX-101.DEF) — 359KB
- mynz-20250630_lab.xml (EX-101.LAB) — 685KB
- mynz-20250630_pre.xml (EX-101.PRE) — 385KB
- ea0258521-6k_mainz_htm.xml (XML) — 869KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the six months ended June 30, 2025 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant's name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events On September 26, 2025, Mainz Biomed N.V. made available its Management's Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025. A copy of the report is attached hereto as Exhibit 99.1. On September 26, 2025, Mainz Biomed N.V. made available its unaudited Financial Statements for the six months ended June 30, 2025. A copy of the report is attached hereto as Exhibit 99.2. This current report on Form 6-K and exhibits 99.1 and 99.2 hereto are hereby incorporated by reference into the Company's Registration Exhibit No. Exhibit 99.1 Management's Discussion and Analysis of Financial Condition and Results of Operations of Mainz Biomed N.V. for the six months ended June 30, 2025 99.2 Unaudited Financial Statements of Mainz Biomed N.V. as of, and for the six months ended, June 30, 2025 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 26, 2025 By: /s/ William J. Caragol Name: William J. Caragol Title Chief Financial Officer 2